EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Track record

Tools

  • Compare
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›ELMD

ELMD

Electromed, Inc.

Next earnings Aug 24, 2026 · consensus $0.32 EPS, $19.7M rev

Last earnings +4.9% on 2026-05-12

Buy
$41.46
▲ +3.52%
$41.46▲ +101.95%
over 1Y
L $18.12EODHDH $41.46
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.5%
1W+8.0%
1M+8.4%
3M+68.9%
YTD+51.4%
1Y+101.9%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Buy
Quality
B
Valuation
Overvalued
Filings
Clean
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy

Revenue grew 17.0% YoY.

The read

The fundamentals carry the rating, but the price is rich (~22% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.

Electromed, Inc. shows $64.0M in FY2025 revenue (+17.0% YoY), a 11.8% net margin, and 17.4% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$35.8M$41.7M$48.1M$54.7M$64.0M
Gross profit$27.3M$31.4M$36.5M$41.7M$50.0M
Operating income$3.14M$2.97M$4.01M$6.58M$9.66M
Net income$2.36M$2.31M$3.17M$5.15M$7.54M
Diluted EPS$0.27$0.26$0.36$0.58$0.85
Net margin6.6%5.5%6.6%9.4%11.8%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$332M
EV / EBITDA—
EV / Sales5.2
EV / FCF29.8
P / FCF31.1
PEG (trailing)1.05
Earnings yield2.2%
FCF yield3.2%

Quality & risk

ROIC (est.)17.2%
Free cash flow$11.1M
Total debt$1.13M
Net cash$14.2M
Altman Z-Score22.71 safe
Piotroski F-Score8/9

Capital returns

Buyback yield2.9%
Dividend yield (est.)—
Shareholder yield2.9%
Shares Δ YoY-3.4%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Routine disclosure cadence — no material red flags in recent filings.
  1. 8-K Earnings results2026-05-12
  2. 10-Q Quarterly report2026-05-12
  3. 8-K Earnings results2026-02-10
  4. 10-Q Quarterly report2026-02-10
  5. 8-K Material agreement2025-12-18
  6. 8-K Shareholder vote2025-11-18
  7. 8-K Earnings results2025-11-12
  8. 10-Q Quarterly report2025-11-12
  9. DEF 14A Proxy statement2025-09-30

Recent filings

all on EDGAR ↗
4Period ending 2026-06-082026-06-09open ↗4Period ending 2026-06-042026-06-08open ↗144Filing2026-06-08open ↗144Filing2026-06-04open ↗SDFiling2026-05-29open ↗4Period ending 2026-05-152026-05-19open ↗144Filing2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗SCHEDULE 13G/AFiling2026-03-26open ↗10-QPeriod ending 2025-12-312026-02-10open ↗8-KPeriod ending 2026-02-102026-02-10open ↗

Quality score

B
ValueGrowthProfitHealthMom.
ValueD
GrowthA
ProfitabilityB
Financial healthA
Momentum—
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✓Net margin above 10%
  • ✓Return on equity above 15%
  • ✓Liabilities below 2× equity
  • ✗P/E below 25

Fair value est.

$32.30

Overvalued -22% vs price

cheapfair valueexpensive

Modified Graham: EPS $0.85 × (8.5 + 1.5 × 22.0% growth) × 1.00 quality = 38.0× multiple. An estimate, not a price target.

Revenue
$64.0M
+17.0% YoY
Net margin
11.8%
ROE
17.4%
P/E
48.8

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$64.0M+17.0%
Net income$7.54M+46.3%
Gross profit$50.0M+19.8%
Operating income$9.66M+46.8%
Diluted EPS$0.85+46.6%
Cash & equivalents$15.3M-4.9%
Total assets$53.8M+3.0%
Total liabilities$10.6M+37.8%
Stockholders' equity$43.2M-3.0%
Gross: 78.1%Op.: 15.1%L/E: 0.25x

Frequently asked

Is Electromed, Inc. (ELMD) a buy?
ELMD currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Revenue grew 17.0% YoY.
What is ELMD's fair value?
A Modified-Graham model based on ELMD's SEC fundamentals estimates a fair value of about $32.30. It is an estimate from reported earnings, not a price target.
Is ELMD overvalued or undervalued?
Against a Modified-Graham fair-value estimate, ELMD currently appears overvalued relative to its SEC-grounded earnings power.
What is Electromed, Inc.'s quality score?
ELMD scores 72.70588235294116/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001488917, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 8:08:43 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 9 sales

2026-06-08
Cunniff James L.
CEO and President
Exercise9.70K @ $17.25$167K
2026-06-08
Cunniff James L.
CEO and President
Sell7.00K @ $36.25$254K
2026-06-08
Cunniff James L.
CEO and President
Sell1.67K @ $36.80$61.5K
2026-06-08
Cunniff James L.
CEO and President
Sell1.03K @ $37.77$38.8K
2026-06-04
Nagel Bradley M.
Chief Financial Officer
Exercise4.33K @ $10.25$44.4K
2026-06-04
Nagel Bradley M.
Chief Financial Officer
Exercise5.27K @ $10.71$56.4K
2026-06-04
Nagel Bradley M.
Chief Financial Officer
Sell11.6K @ $36.34$422K
2026-06-04
Nagel Bradley M.
Chief Financial Officer
Sell181.00 @ $37.11$6.72K
2026-05-15
SKARVAN KATHLEEN
Director
Exercise40.0K @ $3.82$153K
2026-05-15
SKARVAN KATHLEEN
Director
Sell8.15K @ $34.36$280K
2026-05-15
SKARVAN KATHLEEN
Director
Sell19.0K @ $35.24$671K
2026-05-15
SKARVAN KATHLEEN
Director
Sell9.26K @ $36.26$336K

Earnings history

beat/miss · move
2026-05-12Beat +42.2% est▲ +4.90%8-K ↗
2026-02-10Beat +17.2% est▲ +1.63%8-K ↗
2025-11-12Beat +19.6% est▲ +1.08%8-K ↗
2025-08-26—▲ +2.28%8-K ↗
2025-05-13Beat +13.1% est▲ +1.74%8-K ↗
2025-02-11—▼ -2.54%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
ELV Accelerates Clinical Reviews Through Health OS PlatformBullish
finance.yahoo.com· 2026-06-24
Best Momentum Stocks to Buy for June 2ndBullish
finance.yahoo.com· 2026-06-02
New Strong Buy Stocks for June 2ndBullish
finance.yahoo.com· 2026-06-02
Teladoc Health Broadens Virtual Care Reach Through Walmart PlatformBullish
finance.yahoo.com· 2026-05-29
Zacks Industry Outlook Highlights Electromed, Globus Medical and Intuitive SurgicalBullish
finance.yahoo.com· 2026-05-22
3 Medical Instrument Stocks Exploring GenAI to Tackle Industry WoesBullish
finance.yahoo.com· 2026-05-21

Vs tracked universe

compare →

1047 tracked peers · median

EDGAR Score73 vs 67
Revenue growth17.0% vs 7.2%
Net margin11.8% vs 10.5%
Return on equity17.4% vs 12.4%
P/E48.8 vs 25.5

News sentiment

EODHD · 10d
Bullish
+0.18
vs typical · 12 articles

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.